The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial

OBJECTIVES: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) prevents the incidence of community-acquired pneumonia (CAP) caused by influenza (influenza-associated CAP, IA-CAP) or other respiratory viruses in the elderly. METHODS: This analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijts, S.M., Coenjaerts, F.E.J., Bolkenbaas, M., van Werkhoven, C.H., Grobbee, D.E., Bonten, M.J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129545/
https://www.ncbi.nlm.nih.gov/pubmed/29050992
http://dx.doi.org/10.1016/j.cmi.2017.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129545/
https://www.ncbi.nlm.nih.gov/pubmed/29050992
http://dx.doi.org/10.1016/j.cmi.2017.10.006

Ejemplares similares